The tirzepatide shortage that plagued patients for over a year has officially ended, with Eli Lilly's expanded production capacity now ensuring consistent availability of Mounjaro and Zepbound across all dose strengths through the second quarter of 2026. The FDA removed all tirzepatide doses from its official drug shortage list in late 2024, and pharmacy reports confirm that prescriptions are now easier to fill at major chain and independent pharmacies nationwide .

Why Did Tirzepatide Shortages Happen, and Are They Really Over?

From 2023 through 2024, patients struggled to access tirzepatide, the active ingredient in both Mounjaro (used for type 2 diabetes) and Zepbound (approved for weight management). The shortage forced many people to turn to compounded versions of the drug made by specialty pharmacies. Now, Eli Lilly has expanded automated production lines at its facilities in Indiana and North Carolina to meet growing demand. Patients who experienced delays filling prescriptions during the shortage should find the process significantly smoother going forward .

What New Insurance Coverage Is Available for Tirzepatide?

Beyond weight loss, tirzepatide has gained new clinical applications. Following the FDA's late-2024 approval of Zepbound for moderate-to-severe obstructive sleep apnea (OSA), a condition where breathing repeatedly stops and starts during sleep, several major insurance carriers have updated their coverage policies. Sleep medicine specialists report increased patient interest in using tirzepatide for OSA-specific treatment .

• Coverage Requirements: Insurance plans typically require documented diagnosis through a sleep study and a BMI (body mass index) of 30 or higher, which is considered obese for most adults.
• Plan Variation: Coverage details vary significantly by insurance plan, so patients should contact their insurer directly to confirm whether tirzepatide for sleep apnea is covered under their specific policy.
• Growing Acceptance: Sleep medicine specialists are becoming more comfortable prescribing tirzepatide for OSA cases, reflecting growing clinical confidence in the medication's effectiveness for this indication.

How to Access Tirzepatide If You Have Commercial Insurance

• Savings Card Program: Eli Lilly renewed its Mounjaro Savings Card for 2026 with terms similar to 2025, allowing eligible commercially insured patients to access the medication for as little as $25 per month, with maximum savings of $150 per fill.
• Fill Limits: The savings card program covers up to 13 fills over 12 consecutive months, with annual re-enrollment available for continuing patients.
• Government Insurance Exclusion: Patients with Medicare or Medicaid remain ineligible for the savings card program due to federal regulations, though they may have coverage through their specific plan.

For patients seeking compounded tirzepatide, the regulatory landscape has also shifted. The FDA has maintained restrictions on widespread compounding following the drug's removal from the shortage list. State-licensed compounding pharmacies operating under section 503A continue to provide patient-specific compounded tirzepatide in limited circumstances, but mass production by 503B facilities is no longer permitted . Patients interested in compounded versions should verify their pharmacy's state licensing and ask about their specific authorization to compound the medication.

What Major Clinical Trials Are Underway for Tirzepatide?

Beyond current approvals for weight management and type 2 diabetes, tirzepatide is being studied for broader health benefits. The SURPASS-CVOT trial is examining the cardiovascular safety and benefits of tirzepatide in patients with type 2 diabetes and established cardiovascular disease. This long-term outcomes study continues to enroll and follow patients, with initial results expected in 2027. The trial is one of the most closely watched cardiovascular outcomes studies in metabolic medicine, as it will determine whether tirzepatide produces cardiovascular benefits comparable to or exceeding those documented for semaglutide (the active ingredient in Ozempic and Wegovy) in previous trials .

The stabilization of tirzepatide supply marks a significant shift for patients who have struggled with access over the past two years. With consistent availability, expanded insurance coverage for new indications like sleep apnea, and affordable access programs in place, the barriers that once limited tirzepatide use are rapidly disappearing. Patients considering this medication should check with their insurance provider about coverage, explore savings programs if they have commercial insurance, and discuss with their healthcare provider whether tirzepatide is appropriate for their specific health needs.